-
Dr. Wenshi Wang’s Team: Three Latest Research Findings on Hepatitis D and Hepatitis E Included in Conference Exchange
Hepatitis D (HDV) is a viral hepatitis caused by hepatitis D virus (HDV) infection, often occurring as a co-infection or superinfection with hepatitis B virus (HBV). Approximately 90% of chronic hepatitis B patients who become co-infected with HDV develop chronic hepatitis, increasing the risk of adverse outcomes such as liver failure, cirrhosis, and liver cancer.…
-
ESMO Expert Commentary | Roxadustat Non-inferior to Standard Treatment, Poised to Transform Clinical Practice in Chemotherapy-Induced Anemia
Platinum-based, taxane, anthracycline, and other chemotherapy drugs are commonly used in the treatment of various cancers such as breast and lung cancer. However, these chemotherapy agents, known marrow suppressors, can lead to chemotherapy-induced anemia (CIA), resulting in a decline in functional capacity and diminished quality of life for patients. This year’s ESMO conference revealed the…
-
Dr. Chao Wu: Current State and Prospects of Clinical Cure for Hepatitis B
Clinical cure of hepatitis B has been a hot topic in the field of viral hepatitis, and the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the 2023 EASL Congress unveiled numerous advancements in new drug research. Dr. Chao Wu and his team from the Department of…
-
Dr. Yong-an Ye’s Team: Predicting Virological Recurrence in Chronic Hepatitis B with Machine Learning After Entecavir Discontinuation
Currently, most chronic hepatitis B (CHB) patients cannot achieve a cure. While guidelines suggest that some CHB patients can discontinue nucleos(t)ide analogs (NAs) after consolidation therapy, virological recurrence remains common. Early virological recurrence typically predicts disease flare-up; however, there are limited biomarkers for assessing the risk of virological recurrence after treatment cessation. Dr. Yong-an Ye…
-
Dr. Minghua Zheng’s Team: AI-Based Digital Pathology Provides New Insights into NASH Fibrosis Reversal Induced by Lifestyle Intervention
Non-Alcoholic Steatohepatitis (NASH) is a common cause of chronic liver disease, and the degree of liver fibrosis is an important factor determining its clinical prognosis. Lifestyle intervention is the cornerstone of NASH treatment and can improve liver fibrosis. However, the specific effects of lifestyle intervention on micro-level liver fibrosis reversal are not clear. Dr. Minghua…
-
Tumor Cell-Released Kynurenine Biases MEP Differentiation into Megakaryocytes in Individuals with Cancer: A Novel Mechanism for Thrombocytosis and Erythrocytopenia
Thrombocytosis and erythrocytopenia are common hematological abnormalities observed in individuals with advanced cancer. However, the underlying molecular mechanisms for these conditions remain largely unknown. In this study, we aimed to…
-
Targeting Gut Microbial Nitrogen Recycling for Bortezomib Resistance in Multiple Myeloma
Multiple myeloma (MM) is a challenging hematological malignancy characterized by the proliferation of malignant plasma cells. Drug resistance and relapse remain major obstacles in the treatment of MM, emphasizing the…
-
Deciphering STING-Driven Platelet Activation in Septic Thrombosis: A Comprehensive Study Unveiling Molecular Mechanisms and Therapeutic Avenues
Sepsis, a life-threatening condition marked by an overwhelming immune response to infection, often leads to severe complications, including septic thrombosis. Recent studies have uncovered the involvement of the STING (Stimulator…
Connecting Medical Expertise through Media